EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival

Tongxin Li, Jie Liu, Yu Zhou, Shengyuan Huang, Dong Wang, Jianrong Chen, Yong Fu, Ping He iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Tongxin Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Dianjiang People's Hospital of Chongqing, Chongqing, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Mutation, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Chongqing Municipality, Dianjiang County Science and Technology Bureau of Chongqing, Chongqing Medical Scientific Research Project (Joint Project of Chongqing Health Commission and Science and Technology Bureau).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To comprehensively elucidate the genomic and mutational features of lung cancer cases, and lung adenocarcinoma (LUAD), it is imperative to conduct ongoing investigations into the genomic landscape. In this study, we aim to analyze the somatic mutation profile and assessed the significance of these informative genes utilizing a retrospective LUAD cohort.

Methods

A total of 247 Chinese samples were analyzed to exhibit the tumor somatic genomic alterations in patients with LUAD. The Cox regression analysis was employed to identify prognosis‐related genes and establish a predictive model for stratifying patients with LUAD.

Results

In the Dianjiang People's Hospital (DPH) cohort, the top five frequent mutated genes were (Epidermal growth factor receptor) EGFR (68%), TP53 (30%), RBM10 (13%), LRP1B (9%), and KRAS (9%). Of which, EGFR is a mostly altered driver gene, and most mutation sites are located in tyrosine kinase regions. Oncogene pathway alteration and mutation signature analysis demonstrated the RTK‐RAS pathway alteration, and smoking was the main carcinogenic factor of the DPH cohort. Furthermore, we identified 34 driver genes in the DPH cohort, including EGFR (68%), TP53 (30.4%), RBM10 (12.6%), KRAS (8.5%), LRP1B (8.5%), and so on, and 45 Clinical Characteristic‐Related Genes (CCRGs) were found to closely related to the clinical high‐risk factors. We developed a Multiple Parameter Gene Mutation (MPGM) risk model by integrating critical genes and oncogenic pathway alterations in LUAD patients from the DPH cohort. Based on publicly available LUAD datasets, we identified five genes, including BRCA2, Anaplastic lymphoma kinase (ALK), BRAF, EGFR, and Platelet‐Derived Growth Factor Receptor Alpha (PDGFRA), according to the multivariable Cox regression analysis. The MPGM‐low group showed significantly better overall survival (OS) compared to the MPGM‐high group ( p < 0.0001, area under the curve (AUC) = 0.754). The robust performance was validated in 55 LUAD patients from the DPH cohort and another LUAD dataset. Immune characteristics analysis revealed a higher proportion of primarily DCs and mononuclear cells in the MPGM‐low risk group, while the MPGM‐high risk group showed lower immune cells and higher tumor cell infiltration.

Conclusion

This study provides a comprehensive genomic landscape of Chinese LUAD patients and develops an MPGM risk model for LUAD prognosis stratification. Further follow‐up will be performed for the patients in the DPH cohort consistently to explore the resistance and prognosis genetic features.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungMutationLung NeoplasmsHumansMaleFemalePrognosisMiddle AgedAgedRetrospective StudiesErbB ReceptorsBiomarkers, TumorChinaAdultClinical RelevanceEast Asian PeopleReceptors, LDLTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)RNA-Binding Proteins

Stichwörter der Autor:innen

MPGM risk modelclinical characteristic‐related geneslung adenocarcinomamutation profilestargeted sequencing

Substanzen

ErbB ReceptorsBiomarkers, TumorReceptors, LDLTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)RNA-Binding ProteinsEGFR protein, humanLRP1B protein, humanRBM10 protein, humanKRAS protein, human

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Dianjiang People's Hospital of Chongqing, Chongqing, China.
  • Department of Thoracic Surgery, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
  • Department of Cardiac Surgery, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.

ORCID-Profile: Ping He

Förderung

  • Natural Science Foundation of Chongqing Municipality
  • Dianjiang County Science and Technology Bureau of Chongqing
  • Chongqing Medical Scientific Research Project (Joint Project of Chongqing Health Commission and Science and Technology Bureau)

Zitieren

APA

Li, T., Liu, J., Zhou, Y., Huang, S., Wang, D., Chen, J., Fu, Y., & He, P. (2024). Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival. Cancer Medicine. https://doi.org/10.1002/cam4.7227

Vancouver

Li T, Liu J, Zhou Y, Huang S, Wang D, Chen J, et al. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival. Cancer Medicine. 2024. doi:10.1002/cam4.7227

BibTeX
@article{Li2024,
  author = {Li, Tongxin and Liu, Jie and Zhou, Yu and Huang, Shengyuan and Wang, Dong and Chen, Jianrong and Fu, Yong and He, Ping},
  title = {Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7227}
}
Kostenlos starten →